{"id":22534,"date":"2022-10-21T14:23:01","date_gmt":"2022-10-21T12:23:01","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=22534"},"modified":"2022-10-21T14:24:12","modified_gmt":"2022-10-21T12:24:12","slug":"lipum-ab-publ-has-carried-out-a-directed-share-issue","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/lipum-ab-publ-has-carried-out-a-directed-share-issue\/","title":{"rendered":"Lipum AB (publ) has carried out a directed share issue"},"content":{"rendered":"<p class=\"preamble\">Lipum has carried out a directed share issue of approximately SEK 39 million to certain existing and new investors with pronounced long-term interests in the company.<\/p>\n<p>The proceeds will be used primarily to finance the company\u2019s phase I study and for extended pre-clinical studies of the biological drug candidate SOL-116.<\/p>\n<p>Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). Lipum\u2019s shares are listed on Nasdaq First North Growth Market (LIPUM).<\/p>\n<p>Lipum was represented by Mannheimer Swartling in the transaction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lipum has carried out a directed share issue of approximately SEK 39 million to certain existing and new investors with pronounced long-term interests in the\u2026<\/p>\n","protected":false},"author":16,"featured_media":22532,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-22534","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":22534,"sv":22529},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/22534"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=22534"}],"version-history":[{"count":1,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/22534\/revisions"}],"predecessor-version":[{"id":22535,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/22534\/revisions\/22535"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/22532"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=22534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=22534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=22534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}